FY 2000 NCI FUNDING PLAN

Appropriation:

The NCI budget for FY2000 is $3,311.7 million, an increase of $420 million or 14.5% over FY1999 obligations. 

Funding Plan:

Research Project Grants: The largest component of the NCI budget is the Research Project Grant (RPG) category.  In FY1999 over $1.36 billion was devoted to this area; in FY2000 it is currently projected to increase to $1.51 billion, an increase of $142 million or approximately 11% over FY 1999.   It is estimated that an additional 310 RPGs will be funded over last year, predominately through an increased number of non-competing continuation grants. 

Non competing Research Project Grants:
An increase of over $100 million is required to support those non-competing commitments from prior year awards, bringing the total non-competing segment to over $1.058 billion or just short of 1/3rd of the NCI budget.  Each grant will be funded at its full committed level. 

Competing Research Project Grants:
An increase of over 20% in dollars for competing RPGs within the payline is being provided. With these funds, the expectation is that the NCI will fund approximately the same number (740) of competing RO1 grants as last year, within the established paylines. 

Four major issues have put downward pressure on the payline, despite the increase in funding: 

1)   the number of applications assigned to NCI have increased again this year and the number of grants within the payline has increased proportionately;
2)   the average cost being requested is increasing faster than the Biomedical Research Deflator Price Index.  Overall, the increase in average cost requested by RO1 investigators is 20% higher than last year while the Program Project Grant requests are nearly 50% greater than their last award.  In part this reflects that the technology of today's research is more costly. In order to deal with these increasing costs, the NCI policy for FY2000 is to support, on average, a cost increase for both RO1 and PO1 grants of 10% above last year.
3)   the changing mix of grants being supported;  and
4)   increased continuing commitments for non-competing grants. 
The proposed operating budget for FY2000 translates into a success rate of approximately 30% in FY2000. The payline is set at the 22nd percentile for R01 grants funded from the RPG pool.  The disparity between the apparent success rate vs. percentiles reflects two major items: payment of grants as exceptions beyond the payline; and second, differing success rates for non-percentiled award categories funded on the basis of raw score.

Exception RPG Funding:
Approximately 10-12% of the NCI RPG portfolio is funded through an internal exception process.  Included are grants funded as Accelerated Executive Review (AER); and Division-selected exceptions.  In FY2000, $36 million is currently projected for grants that are outside the established payline. Over 100 additional RO1s and PO1s will be funded via this exception process. 

Other Categories Of Research
Division allocations and some of the initiatives linked to extraordinary opportunities or challenge areas of the Bypass Budget are as follows:

  • a 19% increase for the Division of Cancer Treatment and Diagnosis (DCTD) for clinical trials systems, drug discovery and development, diagnostics, repositories, imaging, and radiation therapy; 
  • a 22% increase for the Division of Cancer Control and Population Sciences (DCCPS) for initiatives in the areas of behavior (e.g. tobacco, health communications), epidemiology, genetics, applied research and surveillance; 
  • an 18% increase for the Division of Cancer Prevention (DCP) for activities which include prevention trials, early detection (Prostate, Lung, Colon and Ovary [PLCO], Early Detection Research Network [EDRN]), chemoprevention, nutrition, the Community Clinical Oncology Program (CCOPS) and others; 
  • a 16% increase for the Division of Cancer Biology (DCB) to provide competitive and supplemental funding for collaborative research and for supporting the Mouse Models of Human Cancer Consortium and other preclinical models;
  • a 15% increase for Cancer Centers/Special Programs of Research Excellence (SPOREs) reflecting the growth in both the number and size of center budgets, and the proposed expansion of the SPOREs;
  • a 44% increase for implementation of the 5-year plan for the "K" series awards (K01 Temin awards, K07 prevention and behavioral sciences awards, K22 patient-oriented prevention research award);  K23 patient-oriented mentored career award, and K24 mid-career awards;
  • Intramural Research continues to decline as a percent of the total NCI budget and currently represents under 16% of the NCI budget.

National Cancer Institute | Financial Management Branch